Global Pharmatech Inc. Stock Analysis GBLP
Global Pharmatech, Inc. engages in the discovery, development, manufacturing, and marketing of proprietary drugs developed based on traditional Chinese medicine. The company is headquartered in Changchun, Jilin and currently employs 217 full-time employees. The company went IPO on 2006-05-12. The Company’s main patented products include JUTAI SOFT CAPSULE, QINGXUAN ANTI-HYPERTENSION TABLET, YANREQING TABLET. The firm is also engaged in the manufacture and sales of other proprietary drugs, generics and dietary supplements used to treat symptoms ranging from headaches, coughing and dry mouth to infections and numbness of limbs. The firm also engages in the provision of biotechnology services, including research and development, testing, manufacturing drugs in liquid and solid dose forms, sales and marketing. The firm conducts its business in the domestic and overseas markets.
Read More Global Pharmatech Inc (GBLP) Chart
Key Statistics of Global Pharmatech Inc (GBLP)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.05Volume
-P/E Ratio (TTM)
-52 Week Range
Market Cap
20.76MAvg. Volume
-Dividend Yield
-Financial Metrics & Statements of Global Pharmatech Inc (GBLP)
FAQ's for Global Pharmatech Inc (GBLP)
- According to Musaffa’s Shariah screening methodology, Global Pharmatech Inc (GBLP) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.